title: Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas.
abstract: The aim of this study was to evaluate the expression of E-cadherin as a potential marker for the prognosis of thyroid carcinomas. In normal thyroid (n = 8), the expression of E-cadherin messenger ribonucleic acid levels was uniformly high and seemed to be restricted to thyrocytes. Steady-state messenger ribonucleic acid levels and immunostaining were both completely lost in undifferentiated thyroid carcinomas (n = 7) and were variably reduced in differentiated thyroid carcinomas (n = 44). In a follow-up study during a mean of 4.5 +/- 1.4 yr, E-cadherin messenger ribonucleic acid and immunohistochemical expression were compared with the initial clinicopathological parameters and with locoregional recurrence and the development of nodal or distant metastases in differentiated thyroid carcinomas. Immunohistochemical expression of E-cadherin was greatly reduced with the progression to primary tumor stage 4 (pT4) tumors. In parallel, patients with pT4 tumors had a higher rate of locoregional tumor recurrence and distant metastasis than did the group of patients with pT1-3 tumors. In 5 of 29 patients with pT4 tumors, positive E-cadherin staining of more than 30% of the cells was detected. None of these patients showed signs of a regional recurrence or distant metastases during an observation period of 4.3 +/- 1.1 yr. In 13 patients with E-cadherin-positive tumors, none developed new distant metastases which was in contrast to 7 of the group of 31 patients with less than 30% E-cadherin-positive cells. Thus, E-cadherin expression seems to be associated with the dedifferentiation, progression, and metastatic spread of thyroid carcinomas and may be a useful marker for the prognosis of these tumors.
authors.affiliation: Department of Abdominal and Transplantation Surgery, Medizinische Hochschule Hannover, Germany.
authors.forename: G F
authors.initials: GF
authors.lastname: Scheumman
authors.forename: C
authors.initials: C
authors.lastname: Hoang-Vu
authors.forename: Y
authors.initials: Y
authors.lastname: Cetin
authors.forename: O
authors.initials: O
authors.lastname: Gimm
authors.forename: J
authors.initials: J
authors.lastname: Behrends
authors.forename: R
authors.initials: R
authors.lastname: von Wasielewski
authors.forename: A
authors.initials: A
authors.lastname: Georgii
authors.forename: W
authors.initials: W
authors.lastname: Birchmeier
authors.forename: A
authors.initials: A
authors.lastname: von Zur Mühlen
authors.forename: H
authors.initials: H
authors.lastname: Dralle
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D015152:Blotting, Northern; D015820:Cadherins / Q000032:analysis* / Q000096:biosynthesis; D002277:Carcinoma / Q000473:pathology / Q000601:surgery; D002291:Carcinoma, Papillary / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis / Q000096:biosynthesis; D013961:Thyroid Gland / Q000166:cytology / Q000473:pathology; D013964:Thyroid Neoplasms / Q000473:pathology* / Q000601:surgery; D014158:Transcription, Genetic
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; D012333:RNA, Messenger